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Background: Quality of life (QoL) is increasingly recognized as an important outcome measure in clinical trials. The
Canadian Hemophilia Outcomes-Kids Life Assessment Tool (CHO-KLAT) shows promise for use in China.
Objective: To adapt the CHO-KLAT version 2.0 for use in clinical trials in China.
Methods: Forward and back translations of the CHO-KLAT2.0 were completed in 2008. Between October 2009 and
June 2010, a series of 3 focus groups were held with 20 boys and 31 parents in rural and urban China to elicit
additional concepts, important to their QoL, for the Chinese CHO-KLAT2.0. All of the items identified by boys and
parents were reviewed by a group of experts, resulting in a Chinese version of the CHO-KLAT2.0. This version
underwent a detailed cognitive debriefing process between October 2010 and June 2011. Thirteen patient-parent
pairs participated in this cognitive debriefing process until a stable and clearly understood Chinese version of the
CHO-KLAT2.0 was obtained.
Results: The initial back translation of the Chinese CHO-KLAT2.0 was slightly discrepant from the original English
version on 12 items. These were all successfully adjudicated. The focus groups identified 9 new items that formed
an add-on Socio-Economic Context (SEC) module for China. Linguistic improvements were made after the 2nd, 5th,
7th and 13th cognitive debriefings pairs and affected a total of 18 items. The result was a 35 item CHO-KLAT2.0 and
a SEC module in Simplified Chinese, both of which have good content validity.
Conclusion: This detailed process proved to be extremely valuable in ensuring the items were accurately
interpreted by Chinese boys with hemophilia ages ≤18 years. The need for the additional SEC module highlighted
the different context that currently exists in China with regard to hemophilia care as compared to many Western
countries, and will be important in tracking progress within both rural and urban China over time. Changes based
on the cognitive debriefings suggest that expert verbatim translation alone is not sufficient. The Chinese version of
the CHO-KLAT2.0 is well understood by boys with hemophilia in China. Next steps will be to test its construct
validity and reliability in boys with hemophilia in China.
Keywords: Quality of life, Hemophilia, China, Children, Cross-cultural studiesBackground
Hemophilia is a congenital, X-linked recessive bleeding
disorder resulting in low levels of either factor VIII
(hemophilia A) or factor IX (hemophilia B) that affects
approximately 1 in 5,000 (hemophilia A) and 1 in
20,000-30,000 (hemophilia B) live male births. [1] Spon-
taneous recurrent bleeding into the joints, muscles and* Correspondence: nyoung@laurentian.ca
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reproduction in any medium, provided the orsoft tissues often results in impairments in function.
This is most common in cases with severe hemophilia,
defined by a circulating factor VIII or IX level of < 1%.
These impairments may lead to diminished quality of life
(QoL). Thus, QoL is an important outcome for clinical
research in hemophilia.
Over the last 2 decades there has been significant im-
provement in hemophilia care in China promoted by the
World Federation of Hemophilia (WFH), beginning in
1993. The development of WFH twinning programs with
leading Canadian hemophilia treatment centers began in. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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orative network in China (Tianjin, Guangzhou, Shanghai,
Beijing, Hefei, and Jinan). [2] In the past there has been
limited availability of clotting factor concentrates in
China. Recent literature indicates that 90% of boys in
China over the age of 6 years have significant joint
arthropathy, [3] which may reflect a gap in access to
treatment. China is now benefiting from increased access
to factor replacement therapy. In addition, hemophilia
treatment centers are beginning to be developed in many
cities. These are based on the comprehensive hemophilia
care model. The recent changes in management of
hemophilia in China present a unique opportunity to
study the impact of factor replacement therapy and
enhanced hemophilia care on the quality of life of boys
with hemophilia.
The Canadian Hemophilia Outcomes-Kids Life Assess-
ment Tool (CHO-KLAT) [4,5] was developed in Canada
to measure the quality of life of boys with hemophilia.
Because of its strong measurement properties [5] and re-
cent cross-cultural validation in many European coun-
tries, it was selected for cross-cultural adaptation for use
in China. Disease-specific measures of QoL are import-
ant as we move forward, but none, including the CHO-
KLAT, has been fully tested for use in China. [6] Because
of the relatively rare nature of hemophilia, multi-site
international trials are becoming increasingly common.
Completion of this adaptation will facilitate the inclusion
of Chinese children in international studies, in addition
to measuring the outcome of factor replacement therapy,
during this period of change.
A collaboration between Chinese and Canadian clini-
cians and researchers began in 2007 with the goal of
supporting clinical and research programs in China. The
collaborative QoL research group began in China in
2008. [7] The focus of this group was to prepare for clin-
ical research in China, and specifically to focus on cross-
culturally adapting outcome measures for the clinical
context of China. The purpose of this collaborative study
was to complete the adaptation of the CHO-KLAT for
use in both rural and urban China. The distinction be-
tween rural and urban contexts within China is import-
ant due to differences in access to treatment, both in
terms of access to expert hemophilia professionals and
to availability of factor replacement therapy. Rural was
defined as living more than 50 km outside the city where
they received their treatment.
Methods
The development a new language version of an existing
measure has been well documented in the literature. [8-
11] In China there were 56 different ethnic groups
speaking many different dialects to consider. Because
there has been 20 years of standardized education inChina, and Simplified Chinese is the common written
language used for education, there was consensus that a
Simplified Chinese version would be accessible to the
boys across China. The cross-cultural adaptation process
typically involves 5 steps: initial translation (forward) by
clinicians whose primary language was Chinese; back
translation by a professional translation company; expert
committee review and adjudication; field testing (also
known as cognitive debriefing); and finally a consensus
meeting to approve the initial version of the measure.
Step 1: Forward translation
The initial translation of the CHO-KLAT into Simplified
Chinese was performed by a Chinese physician and a
Chinese research assistant, both of whom were working
at the Hospital for Sick Children, in Canada. The ori-
ginal CHO-KLAT has been recently revised, and this
revised version (denoted as CHO-KLAT2.0) was the
source used for the translation in this study. The Chin-
ese translation was subsequently reviewed by a pair of
clinicians from China.
Step 2: Back translation
The back translation was prepared by a professional
translation company in Toronto.
Step 3: Expert review and adjudication
The back translation results were compared to the ori-
ginal English version of the CHO-KLAT2.0 by the com-
bined China-Canada research team. Discrepancies were
reviewed by the local team in China in conjunction with
members of the original Canadian CHO-KLAT develop-
ment team during a face-to-face meeting. At that time it
became apparent that there may be other issues relevant
to boys in China that were not included in the original
English version of the CHO-KLAT2.0.
Modification of the process for China: focus groups to
identify additional items
Because the culture and health care systems are vastly
different between China and Canada (the original source
of the CHO-KLAT2.0), it was important to carefully ex-
plore the need for potential new items. This was
achieved by holding a series of focus groups with boys
who had hemophilia and separate focus groups with
their parents. We applied the same focus group ap-
proach that had been used in the initial development of
the CHO-KLAT in Canada. [4] Focus groups were held
in Beijing and Chengdu. The latter site was important to
include rural children. Each focus group began with a
series of open-ended probes, designed to promote dis-
cussion of concepts that were important to the quality of
life of boys with hemophilia in China. These concepts
were recorded and displayed for the group to review.
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and added those that were relevant to them, to the list
of concepts on display. The focus group participants
later ranked the importance of the concepts. These con-
cepts and rankings were reviewed by the expert commit-
tee as part of the review and adjudication process.
The China-Canada research team met again to review
the focus group results, and came to consensus on devel-
oping an initial version of the Chinese CHO-KLAT2.0.
The Chinese team included: a pediatric hematologist
(RW), a psychiatrist (JZ), 2 hemophilia nurse specialists
(XW and YZ), and 2 medical students who assisted with
translation (LT and YY). The Canadian team included: a
pediatric hematologist (KHL), an experienced educator
fluent in both English and Chinese (SML), a clinician-
scientist with expertise in the development and testing of
outcome measures for use by children (NY), and a re-
search coordinator (TB). The combined China-Canada
research team met over a 3-day period to achieve con-
sensus on the item content and develop an initial version
of the CHO-KLAT2.0 for use in China. Careful attention
was paid to the linguistic nuances in the item develop-
ment. This resulted in a Chinese version of the CHO-
KLAT2.0 to enter into the cognitive debriefing process.
Step 4: Cognitive debriefing
The next step in the process, cognitive debriefing, was
important to ensure that the Simplified Chinese transla-
tion was understood by both boys with hemophilia and
their parents in a way that was consistent across respon-
dents, as well as being consistent with the original intent
of the items. Cognitive debriefing is an iterative process
in which a questionnaire is administered to participants
using an interview approach based on Jobe’s framework
for assessing cognitive and social-motivational processes.
[12] This process was part of the initial CHO-KLAT2.0
development. [4] We estimated that approximately 10
boys and their parents would be required for the cogni-
tive debriefing process. The inclusion criteria were: able
to read Simplified Chinese, verbally fluent in Chinese,
and be between the ages of 7.0 and 17.99 years of age. A
mix of boys from both rural and urban regions was
recruited from the Beijing Children’s Hospital (BCH).
All participants provided written informed consent and
attended an interview at the treatment center.
A series of cognitive debriefings were held at BCH.
The interview participants were asked to verbalize their
thinking around each item and response set as they pro-
ceeded through the questionnaire. They were also asked
to explain what they thought the items meant. The inter-
viewers kept detailed notes on the participants’ dis-
courses related to each item. The China-Canada research
team coded responses to identify word problems, general
concept problems or response option problems. Theresults were reviewed by this team who made decisions
regarding modification to individual items after each
series of 2 to 3 pairs of debriefings, if necessary. The revi-
sions were evaluated during subsequent repetitions of
the process with new participants, until a stable and well
understood version of all items was achieved.
Step 5: Final adjudication
A final adjudication meeting was held to review the
results of the cognitive debriefing process and come to
consensus on the final version of the CHO-KLAT2.0 for
China.
Ethics approval
Ethical approval for this project was received from Bei-
jing Children’s Hospital and Chengdu Women and Chil-
dren’s Central Hospital. Participants were compensated
for their travel.
Results & discussion
Steps 1, 2 and 3: Forward and back translations and
comparisons
The forward translation was completed in 2008. Two
Chinese clinicians (RW and JZ) completed the back
translation in 2009. The initial back translation of the
Chinese CHO-KLAT2.0 was slightly discrepant from the
original English version on 12 items. The initial adjudi-
cation of discrepancies was completed in August of 2009
and confirmed in mid-October of 2010.
Modification of the process for China
A series of 3 focus groups were held with boys from
both urban and rural China, and an additional 3 groups
were held for their parents. These focus groups were led
by a psychiatrist at Beijing Children’s Hospital (JZ)
whose first language was Chinese and who was experi-
enced in the management of persons with hemophilia in
China. Details are presented in Table 1.
A total of 20 boys and 31 parents were involved in
these focus groups. The boys ranged in age from 4.5 to
16 (mean 9.4) years. Nine had severe (defined as <1%
clotting factor) and 11 had moderate hemophilia
(defined as 1 to 5% clotting factor). Twelve of the 20
were from rural areas. All items were endorsed by at
least 2 focus groups and 77% of the CHO-KLAT2.0 items
were endorsed by at least half of the focus group. These
groups confirmed that all 35 CHO-KLAT2.0 items were
relevant in both rural and urban China. They also identi-
fied 47 potential additional items. These were aggregated
into 9 concepts during the expert panel meeting in Bei-
jing (October 22nd, 2010) and developed into 9 new
items. These were common to many focus groups. Be-
cause most of these were conceptually distinct from the
other CHO-KLAT2.0 items they were combined in an
Table 1 Focus Group Sample Participants
First Group Second Group Third Group Total
Date August 2009 October 2009 October 2010
Region Urban Rural Rural
Boys Sample 8 4 8 20
Boys Age range 7-16 years 6-11 years 5-13 years 5-16 years
(mean) (10.75) (9.12) (9.38) (9.88)
Boys Education 0 pre-school 0 pre-school 1 pre-school 1 pre-school
4 primary 4 primary 6 primary 14 primary
3 middle 0 middle 1 middle 4 middle
1 senior-middle 0 senior-middle 0 senior-middle 1 senior-middle
Boys Severity 5 moderate 2 moderate 4 moderate 11 moderate
3 severe 2 severe 4 severe 9 severe
Parents Sample 10 13 8 31
Total 18 17 16 51
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socio-economic impact of hemophilia and its treatment,
thus the module was named the Socio-Economic Con-
text (SEC) module. This module included items about
stigma (e.g., I felt that other people did not treat me as
well as they treated other children), opportunities for
stable employment (e.g., I worried that I will not be able
to find a good job when I grow up), and access to treat-
ment due to cost (e.g., I worried about the high cost of
factor for my hemophilia treatment).
Step 4: Cognitive debriefing
Seven child-parent pairs were debriefed between Octo-
ber 24th and 26th 2010, by the combined Chinese and
Canadian teams. All of the boys had hemophilia A, 2
had moderate and 5 had severe hemophilia. Six boys had
experience with low-dose prophylaxis (10 units/kg twice
per week) for 3 months (short-term) at the time of the
interviews. The group of caregivers consisted of 6
mothers, and 1 father. Three items were not consistently
interpreted by the first 2 child-parent pairs, thus modifi-
cations were made to these items after the second pair
was completed. Two of these continued to be problem-
atic and were revised a second time after the 5th debrief-
ing pair. Six additional items were also refined at that
time. After the 7th debriefing pair, minor modifications
were made to 2 items to improve the precision of the
wording. The response set was well understood by all
participants.
Six additional child-parent pairs were debriefed be-
tween November 2010 and June 2011, by the Chinese
team independently. The group consisted of 5 boys with
hemophilia A and 1 with hemophilia B. In this group, 4
had moderate and 2 had severe hemophilia. Four boys
had experience with low-dose prophylaxis (10 units/kgtwice per week) for 3 months (short-term) at the time of
the interviews. The group of caregivers consisted of 4
mothers and 2 fathers. Final linguistic improvements
were made after the 13th cognitive debriefing pairs.
The total cognitive debriefing sample ranged in age
from 8 to 17.5 years (mean age of 12.5 years) and 6 of
the 13 lived in rural areas. Seven of the boys had severe
hemophilia and 6 had moderate hemophilia.
Step 5: Final adjudication
The combined results of the 13 cognitive debriefing
pairs were reviewed at 2 adjudication meetings at BCH
on June 13th 2011 and October 22nd, 2011. Minor con-
cerns with wording were identified with 5 CHO-KLAT2.0
items; 3 of these had been revised at least once previ-
ously. In addition, minor concerns were identified with 2
SEC items. Thus subtle refinements in the linguistic
nuances of 7 items were made at this time. Based on ex-
pert consensus, the Chinese version of the CHO-
KLAT2.0 and associated SEC module was finalized.
Throughout the process a total of 18 items underwent
some modification to produce a final version that could
be consistently understood by boys in China.
Conclusion
This paper presents the process of adapting a quality of
life measure for use in China. During the process we
identified the need to return to item generation to deter-
mine if additional items were necessary. This process
resulted in a new Socio-Economic Context module with
9 important items that are unique to the context of
current hemophilia care in China. Although this process
was conducted in China, the lessons learned are likely to
be transportable to other developing countries. It is im-
portant to note that, in order to achieve the goals of the
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ments made by a diverse group of experts from both
China and Canada. The strength of the China-Canada
collaborative relationship was essential to the success of
this project.
Through the process we confirmed that all 35 CHO-
KLAT2.0 items were relevant in China. The nuances of
the language proved challenging, and required more
cognitive debriefings than initially expected. However,
diligence and persistence resulted in a stable version of
the Chinese CHO-KLAT2.0 that was confirmed by con-
sensus. The content validity of the CHO-KLAT2.0 has
been confirmed.
The Chinese version of the CHO-KLAT2.0 requires
validation, and once this has been completed, the meas-
ure will enable comparison of the QoL of Chinese boys
with hemophilia to those in other countries. It will also
be valuable for tracking the changes in QoL over time as
more treatment becomes available in China. We expect
that the SEC module will be particularly valuable to
track changes over time within China.
In conclusion, the final product of this study is a Chin-
ese version of the CHO-KLAT2.0 that is ready to enter
validity testing. Construct validity of this measure will be
conducted as part of a future study.
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